Orthofix reported 1Q20 orthopedic revenue of USD $104.8 million, -3.9% vs. 1Q19. Through January and February, the company was on pace to exceed revenue expectations for the year as late-2019 initiatives began to take hold. Orthofix's spine segment benefitted from $2.9 million in sales of the M6 cervical disc, an increase of 85% vs. the prior year. COVID negatively impacted the company's trauma segment due to a large portion of its portfolio focusing on more elective deformity correction solutions. Biologics declined steeply due to ongoing realignment efforts, procedure deferrals and mid-single-digit price pressure.